Objective
The purpose of our study was to evaluate the prognostic value of platelet reactivity, initial level of inflammation markers and endothelial dysfunction, as well as CYP2C19*2 allele carriage in clinical outcomes after percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (SCAD) during dual antiplatelet therapy (DAPT).
Methods
A prospective, single-center study included 94 patients with SCAD who underwent PCI with DES implantation. Platelet reactivity was determined in all patients using light transmission aggregometry induced with 5μmol/L ADP (LTA-ADP) and VerifyNow before PCI, as well as CYP2C19 genotyping after patient’s discharge. In 74 patients were determined baseline levels of high-sensitivity C-reactive protein, soluble P-selectin, soluble CD40 ligand, highly sensitive IL-6, PAI-1 levels and von Willebrand factor activity.
Methods
A prospective, single-center study included 94 patients with SCAD who underwent PCI with DES implantation. Platelet reactivity was determined in all patients using light transmission aggregometry induced with 5μmol/L ADP (LTA-ADP) and VerifyNow before PCI, as well as CYP2C19 genotyping after patient’s discharge. In 74 patients were determined baseline levels of high-sensitivity C-reactive protein, soluble P-selectin, soluble CD40 ligand, highly sensitive IL-6, PAI-1 levels and von Willebrand factor activity.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
